Background: Placebo and nocebo effects occur in clinical or laboratory medical contexts
after administration of an inert treatment or as part of active treatments and are due to …

Over the years, many have viewed Fibromyalgia syndrome (FMS) as a so-called “functional
disorder” and patients have experienced a concomitant lack of interest and legitimacy from …

The dominant theories of human placebo effects rely on a notion that consciously perceptible
cues, such as verbal information or distinct stimuli in classical conditioning, provide signals …

Background: There is evidence for augmented processing of pain and impaired endogenous
pain inhibition in Fibromyalgia syndrome (FM). In order to fully understand the mechanisms …

… Author links open overlay panel Karin B. Jensen a b , Eva Kosek c d , Rikard Wicksell c e ,
Mike Kemani c e , Gunnar Olsson e f , Julia V. Merle g , Diana Kadetoff c d , Martin Ingvar c d …

Identifying patients who are potential placebo responders has major implications for clinical
practice and trial design. Catechol-O-methyltransferase (COMT), an important enzyme in …

Objective There is vast evidence to support the presence of brain aberrations in patients
with fibromyalgia (FM), and it is possible that central plasticity is critical for the transition from …

Fundamental aspects of human behavior operate outside of conscious awareness. Yet, theories
of conditioned responses in humans, such as placebo and nocebo effects on pain, have …

In response to recent publications from pain neuroimaging experiments, there has been a
debate about the existence of a primary pain region in the brain. Yet, there are few meta-…

<p>Increased pain sensitivity after opioid administration (opioid-induced hyperalgesia) and/or
repeated painful stimuli is an individually varying and clinically important phenomenon. …